Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Why Are AstraZeneca Shares Trading Higher Today

Adding AstraZeneca Plc's (NASDAQ:AZN) Lynparza to Johnson & Johnson's (NYSE:JNJ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed metastatic, castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.

  • The Lynparza combination pared down that risk by 34% over Zytiga alone, according to phase 3 data released at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). 
  • The Lynparza combo added more than eight months to patients' time to disease progression or death, reaching a median of 24.8 months versus 16.6 months for the control group.
  • Related: AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting.
  • AZ and Merck designed the 796-patient phase 3 PROpel trial for all patients independent of HRR status.
  • Results also showed a favorable trend towards improved overall survival (OS) with Lynparza plus abiraterone versus abiraterone alone. 
  • Also See: AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21.
  • However, the difference did not reach statistical significance at this data cut-off (analysis at 29% data maturity). The trial will continue to assess OS as a key secondary endpoint.
  • In July 2017, AstraZeneca and Merck & Co Inc (NYSE: MRK) announced an oncology collaboration to co-develop and co-commercialize Lynparza and Koselugo (selumetinib) for multiple cancer types.
  • Price Action: AZN shares are trading 4.08% at $59.89, MRK shares are up 1.89% at $77.92 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.